Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

NCT06043674 is registered in ClinicalTrials.gov with Christine Ryan as lead sponsor.

NCT NCT06043674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06043674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Lead sponsor
Christine Ryan
Phase
Phase 2
Overall status
Recruiting
Start date
January 22, 2024
Completion date
January 15, 2033
Enrollment
70 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, richter's transformation